Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

Maart 18, 2019
Gent, BELGIË – 18 maart 2019 (17u30 CET) – Sequana Medical NV (“Sequana Medical” of de “Vennootschap“) kondigt vandaag het einde aan van de stabilisatieperiode in het kader van het eerste openbaar aanbod van nieuwe aandelen van de Vennootschap, met de toelating van al haar aandelen tot de verhandeling op de gereglementeerde markt van Euronext...
Read More

PERSBERICHTEN

INSCHRIJVEN OP ONZE PERSBERICHTEN